Phase I Study of the Anti Insulin-Like Growth Factor 1 Receptor (IGF-1R) Monoclonal Antibody, AVE1642, as Single Agent and in Combination With Bortezomib in Patients With Relapsed Multiple Myeloma

Leukemia - United Kingdom
doi 10.1038/leu.2011.4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

A Humanised Anti-Igf-1r Monoclonal Antibody (AVE1642) Enhances Bortezomib-Induced Apoptosis in Myeloma Cells Lacking CD45

British Journal of Cancer
Cancer ResearchOncology
2009English

Phase 1 Pharmacokinetic Study of MK-0646 (Dalotuzumab), an Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody, in Combination With Cetuximab and Irinotecan in Japanese Patients With Advanced Colorectal Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2013English

Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2010English

R1507, an Anti-Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antibody, and EWS/FLI-1 siRNA in Ewing's Sarcoma: Convergence at the IGF/IGFR/Akt Axis

PLoS ONE
Multidisciplinary
2011English

Efficacy of Single-Agent Bortezomib vs. Single-Agent Thalidomide in Patients With Relapsed or Refractory Multiple Myeloma: A Systematic Comparison

European Journal of Haematology
MedicineHematology
2007English

Phase 1 Trial of Vaccination With Autologous Tumor Cells and Antisense Directed Against the Insulin Growth Factor Type 1 Receptor (IGF-1R AS ODN) in Patients With Recurrent Glioblastoma

JHN Journal
2018English

Akt/mTOR Counteract the Antitumor Activities of Cixutumumab, an Anti-Insulin-Like Growth Factor I Receptor Monoclonal Antibody

Molecular Cancer Therapeutics
Cancer ResearchOncology
2011English

Phase I Study of the Anti-FcRH5 Antibody-Drug Conjugate DFRF4539A in Relapsed or Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2019English

Phase 2 Trial of Ixazomib in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib

Blood Cancer Journal
OncologyHematology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy